Active Volume Stock: Global Blood Therapeutics, Inc. (NASDAQ:GBT)

earning reaction history, nasdaq, nyse

Global Blood Therapeutics, Inc. (NASDAQ:GBT)

PiperJaffray Initiates Coverage On Global Blood Therapeutics, Inc. (NASDAQ:GBT)’s stock to Overweight with the price target of $80. This rating was issued on 8/06/18. The stock recently closed its previous session at $38.16 by showing a percentage change of 6.44% from its previous day closing price of $35.85.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Global Blood Therapeutics, Inc. (NASDAQ:GBT) in which Wedbush Maintains Global Blood Therapeutics, Inc. (NASDAQ:GBT) to Outperform by settling a price target of $73 on 8/06/18. Cantor Fitzgerald Maintains the stock to Overweight on 6/28/18 by stationing a price target of $96. Nomura Maintains the company’s stock to Buy on 6/28/18 by setting a price target of $109. H.C. Wainwright Maintains Global Blood Therapeutics, Inc. (NASDAQ:GBT) to Buy with a price target of $125.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) currently has a consensus Price Target of $81.54. While some analysts have a High Price target for the stock of $125 and a Low Price Target of $54.

Several sell side analysts reviewed their recommendations on Global Blood Therapeutics, Inc. (NASDAQ:GBT) where 5 analyst have rated the stock as Strong Buy, 6 analysts said it’s a Buy, 2 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 1.15. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Global Blood Therapeutics, Inc. (NASDAQ:GBT) reported its Actual EPS of $-0.78/share. The analysts offering Earnings Estimates for the company were believing that Global Blood Therapeutics, Inc. (NASDAQ:GBT) could bring EPS of $-0.88/share. The difference between Actual EPS and Estimated EPS was 0.1 Percent. Thus the company showed an Earnings Surprise of 11.4 Percent.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) has a market capitalization of 1.99 Billion. The stock traded with the volume of 3.15 Million shares in the last trading session. The stock touched its high share price of $68.05 on 02/21/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 10/23/17 as $29.95. The company has a 1 Year high price target of $79.86. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of 5.29%. The Moving Average SMA50 is -10.51% while SMA200 is -19.77%.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) is currently showing its ROA (Return on Assets) of -34.6%. The Return on Investment (ROI) is at 0% while it’s Return on Equity (ROE) value stands at -37.4%. The stock currently shows its YTD (Year to Date) performance of -3.02 percent while its Weekly performance value is 20.87%. The Monthly and Yearly performances are -6.59 percent and 17.6 percent respectively. The Relative Volume value measured for Global Blood Therapeutics, Inc. (NASDAQ:GBT) is 3.67. The Average Volume (3 months) is 856.81 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. GBT has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 4.11 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.